Health groups join patent war over spinal muscular atrophy drug

Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Natco Pharma prioritizes profits over patient access to affordable treatment, potentially violating the National Rare Disease Policy.